Bank of America Identifies Top Asia-Pacific Semiconductor Stocks Poised for AI-Driven Growth 
FedEx Pilots and Union Reach Tentative Agreement on 40% Pay Increase 
Apple's Foldable iPhone Faces Engineering Setbacks, Mass Production Timeline at Risk 
China's AI Stocks Surge as Zhipu and MiniMax Hit Record Highs 
Foreign Investors Pour $18.65 Billion into Japanese Stocks Amid Market Stabilization 
Pershing Square Bids €30.40 Per Share to Acquire Universal Music Group in $9.4B Deal 
OpenAI Executive Shake-Up Ahead of Anticipated 2026 IPO 
BHP's Incoming CEO Visits China Amid Pricing Dispute with CMRG 
Ford Issues Major Recall on Over 422,000 Vehicles Due to Windshield Wiper Defect 
Samsung Electronics Posts Eightfold Profit Surge Driven by AI Chip Demand 
Abbott Laboratories Ordered to Pay $53 Million in Premature Infant Formula Lawsuit 
Kia Cuts EV Sales Target for 2030 Amid Slowing Demand and U.S. Policy Shifts 
Britain Courts Anthropic Amid US Defense Department Dispute 
Anthropic's Mythos AI Model Sparks Emergency Cybersecurity Meeting With Top U.S. Bank CEOs 
Bendigo and Adelaide Bank Posts Strong Q3 Earnings, Announces AI-Driven Job Cuts 
Goldman Sachs, ANZ Cut Oil Forecasts Amid U.S.-Iran Ceasefire Hopes 
SOUTH SAN FRANCISCO, Calif., Nov. 10, 2016 -- Achaogen, Inc. (NASDAQ:AKAO), a clinical-stage biopharmaceutical company developing novel antibacterials addressing multi-drug resistant (MDR) gram-negative infections, today announced that the Company will be presenting at the Stifel Healthcare Conference taking place November 15 to 16, 2016, at the Lotte New York Palace Hotel, New York, NY. Achaogen management will present at 2:15 p.m. Eastern Time on Wednesday, November 16th, 2016.
A live audio webcast of the presentation will be available in the "Investors" section of Achaogen’s website, www.achaogen.com. A replay of the presentation will be archived for 30 days following the conference for those unable to listen live.
About Achaogen
Achaogen is a clinical-stage biopharmaceutical company passionately committed to the discovery, development, and commercialization of novel antibacterials to treat MDR gram-negative infections. Achaogen is developing plazomicin, Achaogen’s lead product candidate, for the treatment of serious bacterial infections due to MDR Enterobacteriaceae, including carbapenem-resistant Enterobacteriaceae. Achaogen’s plazomicin program is funded in part with a contract from the Biomedical Advanced Research and Development Authority. Plazomicin is the first clinical candidate from Achaogen’s gram-negative antibiotic discovery engine, and Achaogen has other programs in early and late preclinical stages focused on other MDR gram-negative infections. For more information, please visit www.achaogen.com.
Investor Contact: Hans Vitzthum 212.915.2568 [email protected] Media Contact: Denise Powell 510.703.9491 [email protected]
